Related Experiment Videos
[Second neoplasms in malignant hematologic disorders. Experience from 1978 to 1987]
A Cristoffanini1, C Zapata, A León
1Instituto de Investigaciones Hematológicas Rodolfo Virchow, Facultad de Medicina, Universidad Austral de Chile, Valdivia.
Revista Medica De Chile
|May 1, 1990
Summary
Secondary cancers can occur in patients with hematologic malignancies, even after treatment remission. This study observed new neoplasia in patients treated for blood cancers, suggesting potential links to therapy.
Area of Science:
- Hematology
- Oncology
- Cancer Research
Background:
- Malignant hematologic disorders, including Hodgkin lymphoma, non-Hodgkin lymphoma, Multiple Myeloma, and Chronic Myeloid Leukemia, are treated with radio- and/or chemotherapy.
- Therapeutic interventions for hematologic malignancies may contribute to the development of secondary neoplasms.
Observation:
- A retrospective study reviewed 142 patients with malignant hematologic disorders treated between 1978 and 1987.
- Three patients developed secondary malignancies after treatment for their initial hematologic disorder.
- Additional cases included a patient with acute non-lymphatic leukemia post-gastric cancer chemotherapy and four patients with double neoplasms without prior chemotherapy.
Findings:
- The study observed the occurrence of secondary neoplasia in a small cohort of patients treated for hematologic malignancies.
- The development of new cancers in this population may be multifactorial, potentially linked to prior therapies.
- The presence of secondary cancers in patients without prior chemotherapy warrants further investigation.
Implications:
- These findings highlight the importance of long-term surveillance for secondary malignancies in patients with a history of hematologic cancers.
- Further research is needed to elucidate the specific mechanisms and risk factors associated with therapy-induced or therapy-related secondary cancers.
- The absence of national cancer registries limits the ability to precisely estimate the risk (odds ratios) of developing secondary neoplasia in these patient groups.